Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients

被引：19

作者：

Ogihara, Toshio ^{[1
]}

Saruta, Takao ^{[2
]}

Rakugi, Hiromi ^{[1
]}

Shimamoto, Kazuaki ^{[3
]}

Ito, Sadayoshi ^{[4
]}

Matsuoka, Hiroaki ^{[5
]}

Horiuchi, Masatsugu ^{[6
]}

Imaizumi, Tsutomu ^{[7
]}

Takishita, Shuichi ^{[8
]}

Higaki, Jitsuo ^{[6
]}

Katayama, Shigehiro ^{[9
]}

Saito, Ikuo ^{[2
]}

Shimada, Kazuyuki ^{[10
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Geriatr Med & Nephrol, Suita, Osaka 5650871, Japan

[2] Keio Univ, Osaka, Japan

[3] Sapporo Med Univ, Sch Med, Osaka, Japan

[4] Tohoku Univ, Sch Med, Sendai, Japan

[5] Dokkyo Med Univ, Osaka, Japan

[6] Ehime Univ, Grad Sch Med, Osaka, Japan

[7] Kurume Univ, Sch Med, Osaka, Japan

[8] Univ Ryukyus, Sch Med, Osaka, Japan

[9] Saitama Med Univ, Osaka, Japan

[10] Jichi Med Univ, Osaka, Japan

来源：

HYPERTENSION RESEARCH | 2009年 / 32卷 / 02期

关键词：

clinical trial; combination therapy; olmesartan; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS; TRIAL; AMLODIPINE; MEDOXOMIL; EFFICACY; OUTCOMES;

D O I：

10.1038/hr.2008.31

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The COLM study is an investigator-initiated trial comparing the combination therapy using an angiotensin II receptor blocker (ARB), olmesartan, and a calcium channel blocker (CCB) with that using an ARB and a diuretic in high-risk elderly hypertensive patients. Here we describe the rationale and study design. Olmesartan was administered concomitantly with a long-acting dihydropyridine CCB (ARB/CCB group) or with a low-dose diuretic (ARB/diuretic group) to elderly hypertensive patients with a history of or risk factors for cardiovascular disease. Cardiovascular morbidity and mortality as a primary end point were compared between the two groups, with the target blood pressure (BP) being < 140 mm Hg for systolic BP and < 90 mm Hg for diastolic BR Safety and tolerability will also be investigated. A total of more than 4000 patients were recruited and will be followed up for at least 3 years.

引用

页码：163 / 167

页数：5

共 50 条

[21] Safety and clinical outcome in combination therapy for high-risk elderly hypertensive patients
Umemoto, Seiji
HYPERTENSION RESEARCH, 2015, 38 (02) : 104 - 105
[22] Safety and clinical outcome in combination therapy for high-risk elderly hypertensive patients
Seiji Umemoto
Hypertension Research, 2015, 38 : 104 - 105
[23] Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients
Matsui, Yoshio
Eguchi, Kazuo
O'Rourke, Michael F.
Ishikawa, Joji
Miyashita, Hiroshi
Shimada, Kazuyuki
Kario, Kazuomi
HYPERTENSION, 2009, 54 (04) : 716 - U62
[24] Selective use of calcium channel blockers to treat high-risk hypertensive patients
Ma, DMH
Roht, LH
Hartz, SC
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2000, 9 (01) : 1 - 9
[25] A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients
Wu, Chia-Liang
Wen, Shu-Hui
MEDICINE, 2016, 95 (32)
[26] Combination therapy with Valsartan and calcium channel blockers on morbidity and mortality in high-risk hypertensive patients - Sub-analysis from KYOTO HEART Study
Sawada, T.
Yamada, H.
Kimura, S.
Shiraishi, J.
Matsubara, H.
EUROPEAN HEART JOURNAL, 2010, 31 : 688 - 689
[27] An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone
Kim-Mitsuyama, Shokei
Ogawa, Hisao
Matsui, Kunihiko
Jinnouchi, Tomio
Jinnouchi, Hideaki
Arakawa, Kikuo
KIDNEY INTERNATIONAL, 2013, 83 (01) : 167 - 176
[28] Combined Effect of Angiotensin II Receptor Blocker and Either a Calcium Channel Blocker or Diuretic on Day-by-Day Variability of Home Blood Pressure The Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study
Matsui, Yoshio
O'Rourke, Michael F.
Hoshide, Satoshi
Ishikawa, Joji
Shimada, Kazuyuki
Kario, Kazuomi
HYPERTENSION, 2012, 59 (06) : 1132 - U136
[29] Combination of Amlodipine plus Angiotensin Receptor Blocker or Diuretics in High-Risk Hypertensive Patients A 96-Week Efficacy and Safety Study
Ma, Liyuan
Wang, Wen
Zhao, Yong
Zhang, Yuqing
Deng, Qing
Liu, Mingbo
Sun, Hui
Wang, Jianchun
Liu, Lisheng
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2012, 12 (02) : 137 - 142
[30] Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study
Kojima, Masayoshi
Okubo, Setsuya
Mizubayashi, Ryuichi
Isaka, Naoki
Machida, Hirofumi
Okamoto, Shinya
Hirota, Hisayoshi
Takeuchi, Misao
Kato, Takuya
Nakatani, Kaname
Mizuno, Osamu
Miyagawa, Koichi
Makino, Katsutoshi
Okura, Takanobu
Dohi, Yasuaki
Ito, Masaaki
Kimura, Genjiro
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (07) : 1802 - 1810

← 1 2 3 4 5 →